Access comprehensive financial analyses and make smarter investments - get the Manual of Investments on Amazon!

Smith & Wesson Acquires Savage Arms for $160M

Smith & Wesson Brands said it acquired Savage Arms in a deal valued at $160.0 million, combining one of the best-known U.S. handgun makers with a 130-year-old rifle and shotgun business.

Savage generated about $160 million in net sales over the 12 months ended Sept. 30, 2026. Smith & Wesson said the acquisition is expected to add about $18 million in incremental EBITDA on a full-year basis, before additional synergy gains.

The company said the deal should lift fully diluted earnings per share by about $0.04 for the remainder of fiscal 2027, with full-year accretion of $0.07 per share, excluding acquisition accounting. After initial synergies, that rises to about $0.10 per share.

Smith & Wesson valued the business at about 7.9 times Savage’s adjusted EBITDA, after factoring in expected initial annual run-rate synergies of $2.5 million.

The purchase price included about 9 million Smith & Wesson shares, priced at $13.62 each, and $37.5 million in cash. Following the closing, JDH Capital owns 16.7% of Smith & Wesson’s outstanding common stock and has a board seat on the now seven-member board.

Smith & Wesson said its pro forma net leverage ratio stands at 1.16 following the transaction. Following these announcements, the company's shares moved 0.0%, and are now trading at a price of $14.78. For the full picture, make sure to review SMITH & WESSON BRANDS, INC.'s 8-K report.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.

IN FOCUS